NCT02920541View on ClinicalTrials.gov

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 24, 2018

Study Completion Date

May 24, 2018

Conditions
Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)
Interventions
DRUG

S 055746

S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.

Trial Locations (5)

Unknown

The Alfred Hospital, Melbourne

Royal Melbourne Hospital, Parkville

Institut Paoli Calmettes, Marseille

Hôpital Saint Louis, Paris

Centre Hospitalier Lyon Sud, Pierre-Bénite

All Listed Sponsors
collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER

NCT02920541 - Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter